Statera Biopharma Inc (STAB)
Statera Biopharma Inc. (STAB) is a common stock listing on OTC Markets tied to a clinical-stage biopharmaceutical company. The business focuses on developing immunotherapy candidates for autoimmune conditions, blood-related disorders, infectious diseases, and cancer. Its pipeline includes programs associated with Crohn’s disease, hematology, pancreatic cancer, COVID-19, fibromyalgia, and multiple sclerosis. The company says its work is built around a platform intended to influence immune responses and support a return to normal immune function. Formerly known as Cytocom, Inc., the company adopted the Statera Biopharma name in September 2021. It is based in Fort Collins, Colorado, and is a subsidiary of Biostax Corp.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-STAB
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
7.258 K
|
—
|
—
|
—
|
—
|
—
|
—
|
